Literature DB >> 11891515

Respiratory syncytial virus infections in children.

Mary Allen Staat1.   

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in young children in both developing and developed countries. By age 2, nearly all children have been infected by RSV.The clinical manifestations range from mild upper respiratory symptoms to bronchiolitis and pneumonia. First infections are nearly always symptomatic and frequently cause lower respiratory tract disease, whereas subsequent infections are generally milder. Although children with underlying conditions such as prematurity, chronic lung disease, congenital heart disease, and immuno-suppression are at high risk for severe disease, many children without underlying conditions require hospitalization. Treatment is supportive. Immunoprophylaxis with palivizumab or RSV immune globulin may benefit children born prematurely, especially those with bronchopulmonary dysplasia. To date, the development of an effective vaccine has been unsuccessful.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891515     DOI: 10.1053/srin.2002.31688

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  15 in total

1.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes.

Authors:  Amit Agrawal; Ralph A Tripp; Larry J Anderson; Shuming Nie
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats.

Authors:  Myra N Widjojoatmodjo; Jolande Boes; Marleen van Bers; Yvonne van Remmerden; Paul J M Roholl; Willem Luytjes
Journal:  Virol J       Date:  2010-06-02       Impact factor: 4.099

6.  Respiratory syncytial virus infection reduces lung inflammation and fibrosis in mice exposed to vanadium pentoxide.

Authors:  Elizabeth A Turpin; Aurita Antao-Menezes; Mark F Cesta; James B Mangum; Duncan G Wallace; Edilberto Bermudez; James C Bonner
Journal:  Respir Res       Date:  2010-02-22

Review 7.  The host response and molecular pathogenesis associated with respiratory syncytial virus infection.

Authors:  Christine M Oshansky; Wenliang Zhang; Elizabeth Moore; Ralph A Tripp
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

Review 8.  Severe bronchiolitis in children.

Authors:  Sanjay Jhawar
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

9.  RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

Authors:  Rene Alvarez; Sayda Elbashir; Todd Borland; Ivanka Toudjarska; Philipp Hadwiger; Mathias John; Ingo Roehl; Svetlana Shulga Morskaya; Rick Martinello; Jeffrey Kahn; Mark Van Ranst; Ralph A Tripp; John P DeVincenzo; Rajendra Pandey; Martin Maier; Lubomir Nechev; Muthiah Manoharan; Victor Kotelianski; Rachel Meyers
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

10.  Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness.

Authors:  Koichi Hashimoto; Barney S Graham; Mark W Geraci; Garret A FitzGerald; Karine Egan; Weisong Zhou; Kasia Goleniewska; Jamye F O'Neal; Jason D Morrow; Russell K Durbin; Peter F Wright; Robert D Collins; Tatsuo Suzutani; R Stokes Peebles
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.